Cite
de Bruijn W, Ibáñez C, Frisk P, et al. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol. 2016;7:197doi: 10.3389/fphar.2016.00197.
de Bruijn, W., Ibáñez, C., Frisk, P., Bak Pedersen, H., Alkan, A., Vella Bonanno, P., Brkičić, L. S., Bucsics, A., Dedet, G., Eriksen, J., Fadare, J. O., Fürst, J., Gallego, G., Godói, I. P., Guerra Júnior, A. A., Gürsöz, H., Jan, S., Jones, J., Joppi, R., Kerman, S., Laius, O., Madzikwa, N., Magnússon, E., Maticic, M., Markovic-Pekovic, V., Massele, A., Ogunleye, O., O'Leary, A., Piessnegger, J., Sermet, C., Simoens, S., Tiroyakgosi, C., Truter, I., Thyberg, M., Tomekova, K., Wladysiuk, M., Vandoros, S., Vural, E. H., Zara, C., & Godman, B. (2016). Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Frontiers in pharmacology, 7197. https://doi.org/10.3389/fphar.2016.00197
de Bruijn, Winnie, et al. "Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future." Frontiers in pharmacology vol. 7 (2016): 197. doi: https://doi.org/10.3389/fphar.2016.00197
de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol. 2016 Jul 22;7:197. doi: 10.3389/fphar.2016.00197. eCollection 2016. PMID: 27516740; PMCID: PMC4964878.
Copy
Download .nbib